This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

. 2021 Jan;57(1):106171.

doi: 10.1016/j.ijantimicag.2020.106171.

Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial"

Mohamed O Saad¹

Affiliations

PMID: 33408024
PMCID: PMC7781510
DOI: 10.1016/j.ijantimicag.2020.106171

Letter to the editor about "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial"

Mohamed O Saad. Int J Antimicrob Agents. 2021 Jan.

. 2021 Jan;57(1):106171.

doi: 10.1016/j.ijantimicag.2020.106171.

Author

Mohamed O Saad¹

Affiliation

¹ Department of Pharmacy, Al-Wakra Hospital, Hamad Medical Corporation, PO Box 82228 Doha, Qatar. Electronic address: msaad4@hamad.qa.

PMID: 33408024
PMCID: PMC7781510
DOI: 10.1016/j.ijantimicag.2020.106171

No abstract available

PubMed Disclaimer

Conflict of interest statement

Declaration of Competing Interest None.

Similar articles

Referring to the study: Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open label non-randomized clinical trial.
Dos Santos MR. Dos Santos MR. Int J Antimicrob Agents. 2021 Jan;57(1):106176. doi: 10.1016/j.ijantimicag.2020.106176. Int J Antimicrob Agents. 2021. PMID: 33408022 Free PMC article. No abstract available.
Focus on clinical outcomes of "Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial".
Wambier CG. Wambier CG. Int J Antimicrob Agents. 2021 Jan;57(1):106175. doi: 10.1016/j.ijantimicag.2020.106175. Int J Antimicrob Agents. 2021. PMID: 33408021 Free PMC article. No abstract available.
Effect estimation of hydroxychloroquine for COVID-19: a secondary analysis of an open label non-randomized clinical trial.
Parra-Lara LG, Martinez-Arboleda JJ, Isaza-Pierotti DF, Rosso F. Parra-Lara LG, et al. Int J Antimicrob Agents. 2021 Jan;57(1):106172. doi: 10.1016/j.ijantimicag.2020.106172. Int J Antimicrob Agents. 2021. PMID: 33408017 Free PMC article. No abstract available.
Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.
Fiolet T, Guihur A, Rebeaud ME, Mulot M, Peiffer-Smadja N, Mahamat-Saleh Y. Fiolet T, et al. Clin Microbiol Infect. 2021 Jan;27(1):19-27. doi: 10.1016/j.cmi.2020.08.022. Epub 2020 Aug 26. Clin Microbiol Infect. 2021. PMID: 32860962 Free PMC article.
Combination of Hydroxychloroquine Plus Azithromycin As Potential Treatment for COVID-19 Patients: Safety Profile, Drug Interactions, and Management of Toxicity.
Hache G, Rolain JM, Gautret P, Deharo JC, Brouqui P, Raoult D, Honoré S. Hache G, et al. Microb Drug Resist. 2021 Mar;27(3):281-290. doi: 10.1089/mdr.2020.0232. Microb Drug Resist. 2021. PMID: 33729874 Free PMC article. Review.

See all similar articles

Cited by

Effect of hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial, an update with an intention-to-treat analysis and clinical outcomes.
Gautret P, Hoang VT, Lagier JC, Raoult D. Gautret P, et al. Int J Antimicrob Agents. 2021 Jan;57(1):106239. doi: 10.1016/j.ijantimicag.2020.106239. Int J Antimicrob Agents. 2021. PMID: 33408029 Free PMC article. Clinical Trial. No abstract available.
METRNL mitigates oxidative stress and inflammatory drawbacks in ovalbumin/lipopolysaccharide-induced allergic airway diseases via the IKK/IκB/NF-κB signaling pathway.
Khodir SA, Shaban AM, Sweed E, El-Aziz NMA, Mostafa BA, Latif AAA, El-Kalshy MM, Elgizawy EI. Khodir SA, et al. Naunyn Schmiedebergs Arch Pharmacol. 2025 Apr 17. doi: 10.1007/s00210-025-04070-6. Online ahead of print. Naunyn Schmiedebergs Arch Pharmacol. 2025. PMID: 40244452
Efficacy of Ivermectin, Chloroquine/Hydroxychloroquine, and Azithromycin in Managing COVID-19: A Systematic Review of Phase III Clinical Trials.
Sansone NMS, Boschiero MN, Marson FAL. Sansone NMS, et al. Biomedicines. 2024 Sep 27;12(10):2206. doi: 10.3390/biomedicines12102206. Biomedicines. 2024. PMID: 39457519 Free PMC article. Review.

References

1. Gautret P., Lagier J.-C., Parola P., Hoang V.T., Meddeb L., Mailhe M. Hydroxychloroquine and azithromycin as a treatment of COVID-19: results of an open-label non-randomized clinical trial. Int J Antimicrob Agents. 2020;56(1) - PMC - PubMed
1. Guo D., Cai Y., Chai D., Liang B., Bai N., Wang R. The cardiotoxicity of macrolides: a systematic review. Pharmazie. 2010;65:631–640. - PubMed
1. O'Laughlin J.P., Mehta P.H., Wong B.C. Life Threatening Severe QTc Prolongation in Patient with Systemic Lupus Erythematosus due to Hydroxychloroquine. Case Reports Cardiol. 2016:2016. doi: 10.1155/2016/4626279. - DOI - PMC - PubMed

Publication types

Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions
Actions
Actions
Actions
Actions

LinkOut - more resources

Full Text Sources
Other Literature Sources
- scite Smart Citations